BRIEF—Daiichi Sankyo restructures vaccines business

Japan’s Daiichi Sankyo has announced it is restructuring its vaccines business, Kitasato Daiichi Sankyo Vaccine, merging it into the parent company.

The manufacturing functions will be transferred to Daiichi Sankyo Biotech, with the purpose of ensuring “stable manufacturing and quality improvement.”

Functions other than manufacturing will be transferred to Daiichi Sankyo, and Kitasato Daiichi Sankyo Vaccine will be dissolved.